

## Global spotlight 23.2: Key additions for the second half of November 2022



There is one update to a living evidence synthesis already included in the public-health measures part of the COVID-END inventory of ‘best’ evidence syntheses\*, 13 updates to living evidence syntheses already included in the clinical management parts of the inventory, and one update to a living evidence synthesis already included in the health-system arrangements part of the inventory.

*\*COVID-END assigns ‘best’ status to evidence syntheses based on an assessment of how up-to-date they are (i.e., the date of the last search, with priority given to living reviews), quality (using the AMSTAR tool), and whether there is an evidence profile available (e.g., GRADE).*

Taxonomy section	Title	Type of synthesis	Criteria for best evidence synthesis		
			Date of last search	Quality (AMSTAR) rating	Evidence profile (e.g., GRADE) available
Public-health measures	<a href="#">Evidence suggests insufficient protection against COVID-19 infection produced by the Omicron variant of concern immediately after receiving a booster dose with no decrease in vaccine effectiveness up to 20 weeks, while vaccine effectiveness against hospitalization was reported to be reduced after 20 weeks of receiving a primary vaccine series or a booster shot</a>	Update to living rapid review	2022-11-09	8/9	No
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Bamlanivimab] In hospitalized COVID-19 patients, bamlanivimab may make little or no difference in mortality, clinical improvement, and disease progression, while it may not increase the risk of serious adverse events for hospitalized and outpatients; in COVID-19 outpatients, it may slightly reduce the risk of hospitalization or death, and it may slightly increase clinical improvement</a>	Update to living review	2022-11-18	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Ensitrelvir] Using ensitrelvir to treat COVID-19 patients may make little or no difference in hospitalization or death and it probably increases viral negative conversion; it probably increases the risk of any adverse event</a>	Update to living review	2022-11-18	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Regdanvimab] Using regdanvimab to treat COVID-19 outpatients probably makes little or no difference in mortality, it probably reduces the risk of hospitalization or death, and it may increase viral negative conversion; it probably does not increase the risk of serious adverse events</a>	Update to living review	2022-11-18	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Sarilumab] Using sarilumab for hospitalized COVID-19 patients probably makes little or no difference in clinical improvement, while it may slightly increase serious adverse events; its effects on other outcomes are uncertain</a>	Update to living review	2022-11-18	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Sotrovimab] Among COVID-19 hospitalized patients, sotrovimab may not have an effect on mortality and disease progression, it probably slightly increases clinical improvement and it may substantially increase serious adverse events; in outpatients, it probably does not have an effect on mortality, it probably reduces the risk of hospitalization or death, and it probably does not increase serious adverse events</a>	Update to living review	2022-11-18	10/11	Yes
Clinical management of COVID-19 and	<a href="#">[Tocilizumab] Among hospitalized patients, tocilizumab slightly reduces mortality at 28 days, it</a>	Update to living review	2022-11-18	10/11	Yes

pandemic-related health issues	<a href="#">probably slightly increases the incidence of clinical improvement, and it may slightly reduce disease progression; it probably makes little or no difference in the incidence of adverse events</a>				
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Tenofovir + emtricitabine] Using tenofovir + emtricitabine to treat COVID-19 outpatients may not have an effect on hospitalization or death, while its effects on other outcomes are currently uncertain</a>	Update to living review	2022-11-11	10/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">No clear evidence suggests a worsening of mental health symptoms as a result of the COVID-19 pandemic when comparing mental health prior to and during the pandemic, but small negative impact might have been felt by women [Review of studies of variable quality with substantial heterogeneity among their findings]</a>	Update to living review	2022-04-11	6/11	No
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Corticosteroids] Using corticosteroids probably reduces 30-days mortality in hospitalized COVID-19 patients, while its effects on long-term mortality are uncertain; the effects on other outcomes (including adverse events) are uncertain as well as the most effective dosage and timing</a>	Update to living review	2022-01-06	11/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">Global variations of SARS-CoV-2 infection rates and burden among pregnant women have been documented [Review of studies with substantial heterogeneity among some of its outcomes]</a>	Update to living review	2021-04-27	7/11	No
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Chlorpheniramine (nasal)] The effects of using nasal chlorpheniramine to treat COVID-19 patients are currently uncertain</a>	Update to living rapid review	2022-11-07	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Molnupiravir] Using molnupiravir to treat COVID-19 patients probably has no important effect on hospitalizations while it probably increases symptom resolution; it may not increase severe adverse events</a>	Update to living rapid review	2022-11-07	7/11	Yes
Clinical management of COVID-19 and pandemic-related health issues	<a href="#">[Vidofludimus calcium] The effects of using vidofludimus calcium to treat COVID-19 patients are currently uncertain</a>	Update to living rapid review	2022-11-07	7/11	Yes
Health-system arrangements	<a href="#">The effects of hospital visitor policies to reduce COVID-19 transmission are uncertain and poorly studied [Review of studies of mainly low quality]</a>	Update to living review	2021-04-01	4/9	No